Updated · AI-assisted evidence analysis
Cosequin Joint Health Supplement for Dogs Chewable Tablets with MSM Review 2026: What Does the Evidence Show?
Cosequin's joint claims rest on mixed ingredient research, not this product. — Overhyped
-
"Glucosamine and chondroitin help dogs' joints"
A 35-dog trial found improvement by day 70, but it compared against carprofen rather than a placebo and used subjective vet scoring. A 2022 meta-analysis reported a very marked non-effect and advised against recommending these products for pain in dogs and cats.
-
"Reviews support the combination"
A 2007 review gave a moderate level of comfort to one trial of a chondroitin, glucosamine and manganese ascorbate combination. A 2017 review described the evidence as limited and conflicting.
-
"Helps support healthy cartilage"
One 16-dog surgical model study saw changes in joint fluid markers. The effect was no longer significant when compared against each dog's non-operated knee. The 2022 authors say that, to their knowledge, no approach has shown it slows OA progression.
Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. → · A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. → -
"MSM provides sulfur to support joints"
No dog research on MSM was found in the retrieved sources. That is absence of evidence in this search, not evidence that MSM fails.
Claims vs Evidence
4 claims assessed. Support depends on the study results, formulation, and population. Matching an ingredient or dose alone does not establish a benefit.
"Supports joint health in dogs"
Stretch
Dog evidence on glucosamine plus chondroitin is thin and points both ways. Positive results come from a small trial without a placebo and a review of one trial; the 2022 meta-analysis reported a very marked non-effect on pain. None tested this tablet.
Randomised double-blind, positive-controlled trial of glucosamine/chondroitin sulfate in dogs with osteoarthritis
Randomised, double-blind, multicentre trial with carprofen as positive control; no placebo group mentioned in the abstract; vet-scored subjective outcomes · ingredient
Significant improvement in pain, weight-bearing and severity scores by day 70 (P<0.001). Onset of response was slower than with carprofen.
Limitations: Small sample, subjective scoring, no placebo mentioned, abstract only; effect sizes unavailable
- Species
- dog
- Participants / condition
- 35 dogs with confirmed hip or elbow osteoarthritis
- Formulation
- Oral glucosamine hydrochloride plus chondroitin sulfate combination; brand and manganese/MSM content not reported in abstract
- Studied amount, not dosing advice
- Not reported in abstract
- Duration
- 70 days of treatment; reassessed at day 98 after withdrawal
- Funding / conflicts
- Not reported in abstract; unavailable
Systematic review of clinical trials of treatments for osteoarthritis in dogs
Systematic review of 16 clinical trials, searched before May 2006, using an FDA evidence scoring system · different formulation
Moderate level of comfort for the combination, based on one trial rated type I
Limitations: Based on a single trial for this combination; old search date; abstract only
- Species
- dog
- Participants / condition
- Dogs with osteoarthritis across 16 trials; one trial tested the chondroitin/glucosamine HCl/manganese ascorbate combination
- Formulation
- Chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate; MSM not mentioned; brand not named in abstract
- Studied amount, not dosing advice
- Not reported in abstract
- Duration
- Not reported in abstract
- Funding / conflicts
- Not reported in abstract; unavailable
Glucosamine and chondroitin use in canines for osteoarthritis: a review
Review article of the canine literature · ingredient
Described evidence as limited and conflicting, with a paucity of well-designed clinical studies
Limitations: Abstract only; no pooled effect reported
- Species
- dog
- Participants / condition
- Dogs with osteoarthritis; study counts not reported in abstract
- Formulation
- Glucosamine HCl and chondroitin sulfate; product-specific details not reported
- Studied amount, not dosing advice
- Not reported in abstract
- Duration
- Not reported in abstract
- Funding / conflicts
- Not reported in abstract; unavailable
2022 systematic review and meta-analysis of enriched diets and nutraceuticals in canine and feline osteoarthritis
Systematic review and meta-analysis (PROSPERO registered); 72 trials, 69 in dogs and 3 in cats; quality comparisons used canine publications only · ingredient
Authors reported a very marked non-effect of chondroitin-glucosamine nutraceuticals and recommended they no longer be recommended for pain management in canine and feline OA.
Limitations: The abstract's conclusion covers dogs and cats together; the excerpt omits results tables and does not give dog-only efficacy figures
- Species
- dog
- Participants / condition
- Dogs with osteoarthritis in the dog-identified trials; nine trials in the chondroitin-glucosamine category
- Formulation
- Chondroitin-glucosamine nutraceuticals, various combinations; not this product
- Studied amount, not dosing advice
- Not reported in the retrieved excerpt
- Duration
- Not reported in the retrieved excerpt
- Funding / conflicts
- No proprietary funding; indirect academic grant support. Authors report past work for several animal-health companies and declare no conflict directly related to the review.
"Glucosamine and chondroitin sulfate work together to support joint health"
Stretch
The studies tested the two together, so no retrieved study shows they work better combined than apart. Results for the pair are mixed.
Randomised double-blind, positive-controlled trial of glucosamine/chondroitin sulfate in dogs with osteoarthritis
Randomised, double-blind, multicentre trial with carprofen positive control; no placebo mentioned in the abstract · ingredient
Improved pain, weight-bearing and severity scores by day 70; slower onset than carprofen
Limitations: No placebo mentioned, subjective scoring, small sample, abstract only. It tested the pair together, not each alone.
- Species
- dog
- Participants / condition
- 35 dogs with confirmed hip or elbow osteoarthritis
- Formulation
- Glucosamine hydrochloride plus chondroitin sulfate; brand not reported in abstract
- Studied amount, not dosing advice
- Not reported in abstract
- Duration
- 70 days; reassessed at day 98
- Funding / conflicts
- Not reported in abstract; unavailable
2022 systematic review and meta-analysis of enriched diets and nutraceuticals in canine and feline osteoarthritis
Systematic review and meta-analysis; 69 dog and 3 cat trials; quality comparisons used canine publications only · ingredient
Very marked non-effect of chondroitin-glucosamine nutraceuticals; authors advised against recommending them for pain management
Limitations: The abstract's conclusion covers dogs and cats together; the category groups several combinations; excerpt omits results
- Species
- dog
- Participants / condition
- Dogs with osteoarthritis in dog-identified chondroitin-glucosamine trials
- Formulation
- Various chondroitin-glucosamine combinations; not this product
- Studied amount, not dosing advice
- Not reported in the retrieved excerpt
- Duration
- Not reported in the retrieved excerpt
- Funding / conflicts
- No proprietary funding; authors disclose past work for several animal-health companies, none declared as directly related.
Glucosamine and chondroitin use in canines for osteoarthritis: a review
Review article · ingredient
Evidence limited and conflicting; few well-designed clinical studies
Limitations: Abstract only
- Species
- dog
- Participants / condition
- Dogs with osteoarthritis; counts not reported in abstract
- Formulation
- Glucosamine HCl and chondroitin sulfate
- Studied amount, not dosing advice
- Not reported in abstract
- Duration
- Not reported in abstract
- Funding / conflicts
- Not reported in abstract; unavailable
"Helps support your dog's healthy cartilage"
Stretch
The only cartilage-related dog data are joint fluid markers in a small surgical model, and the effect was no longer significant under one analysis. The 2022 authors say that, to their knowledge, no approach has shown it slows OA progression.
Oral chondroitin sulfate, glucosamine HCl and manganese ascorbate and synovial fluid markers in a canine CCL transection model
Randomised experimental study of surgically induced knee instability; four groups · different formulation
Treated dogs had higher synovial fluid 3B3 and 7D4 epitope levels at 3 months. When expressed as a ratio to the non-operated knee, the treatment effect was no longer significant. Authors concluded these compounds may modulate cartilage matrix metabolism.
Limitations: Tiny groups, induced injury rather than natural OA, lab markers rather than pain or function, abstract only
- Species
- dog
- Participants / condition
- 16 adult dogs with unilateral cranial cruciate ligament transection (groups of 3 to 5)
- Formulation
- Chondroitin sulfate, glucosamine HCl and manganese ascorbate; MSM not mentioned; brand not named in abstract
- Studied amount, not dosing advice
- Not reported in abstract
- Duration
- 5 months, with fluid sampled at 0, 1, 3 and 5 months
- Funding / conflicts
- Not reported in abstract; unavailable
2022 systematic review and meta-analysis of enriched diets and nutraceuticals in canine and feline osteoarthritis
Systematic review and meta-analysis; 69 dog and 3 cat trials · ingredient
In the introduction, the authors state that to their knowledge no therapeutic approach has any indication of a delayed effect on OA progression, so terms like chondroprotective do not yet apply
Limitations: Review focused on analgesic efficacy, not cartilage structure; the statement is from the introduction, not a result; excerpt omits results
- Species
- dog
- Participants / condition
- Dogs with osteoarthritis in dog-identified trials
- Formulation
- Various nutraceuticals; chondroitin-glucosamine category not this product
- Studied amount, not dosing advice
- Not reported in the retrieved excerpt
- Duration
- Not reported in the retrieved excerpt
- Funding / conflicts
- No proprietary funding; authors disclose past work for several animal-health companies, none declared as directly related.
"MSM provides sulfur, which helps support joint health"
No evidence found
No dog research on MSM appeared in the retrieved sources. The 2022 meta-analysis excerpt and the 2023 COAST guideline excerpt do not discuss it. This is absence of evidence in this search, not a finding that MSM fails.
Signals
- The '#1 vet recommended' claim rests on a survey footnote, and the reviewed material gives no survey methods.
- 'Backed by science' is not matched by any exact-product trial in this search; the research found tested other combinations.
- 'Thorough quality inspections' names no third-party tester, and Nutramax does not appear on the NASC member list checked 2026-11-03.
- 'Over 25 years' describes time on the market, which the reviewed material does not link to proof of benefit.
- The label prints per-tablet amounts: glucosamine HCl 600 mg, chondroitin sulfate 300 mg, MSM 250 mg, manganese 3 mg.
Dose vs studies
Label amounts at the label's daily directions, per kg of body weight, compared with what dogs studies used. This compares the label with research. It is not dosing advice.
Label: 600 mg per chewable tablet
Studied: No established amount in dogs
Label: 300 mg per chewable tablet
Studied: No established amount in dogs
Label: 250 mg per chewable tablet
Studied: No established amount in dogs
Evidence checks
Species and formulation relevance
All applicable studies were in dogs, but none tested this chewable tablet. The closest tested chondroitin, glucosamine and manganese ascorbate; MSM was not mentioned and the brand was not named. No exact-product trial was found in this search.
Label transparency
The manufacturer page lists per-tablet amounts and a weight-based serving table. The retrieved abstracts did not report studied amounts, so the label amounts cannot be compared with a studied range.
Independent quality testing
The reviewed material shows no named third-party test of this product. Nutramax Laboratories does not appear in the NASC member list checked 2026-11-03. That is a company-level record and says nothing about this product's contents.
Strength of dog evidence
Positive dog findings come from a small trial without a placebo mentioned and a small surgical model. The 2022 meta-analysis reported a very marked non-effect for chondroitin-glucosamine products. Funding was not reported in most abstracts.
Sources (8)
- 1. Cosequin Joint Health Supplement for Dogs Chewable Tablets with MSM: manufacturer product page →
Manufacturer · Accessed 2026-11-04
- 2. NASC member list, checked 2026-11-03 →
Quality standard · Accessed 2026-11-03
- 3. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. →
Study · Accessed 2026-11-04
- 4. Systematic review of clinical trials of treatments for osteoarthritis in dogs. →
Research review · Accessed 2026-11-04
- 5. Glucosamine and chondroitin use in canines for osteoarthritis: A review. →
Research review · Accessed 2026-11-04
- 6. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. →
Research review · Accessed 2026-11-04
- 7. COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis. →
Research review · Accessed 2026-11-04
- 8. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. →
Study · Accessed 2026-11-03
How this report was produced
AI-assisted evidence analysis. We reviewed published material, not physical products.
Automated source and evidence checks completed on 2026-11-04. These checks are not veterinary review.
Research scope and outstanding checks
Searched Europe PMC-style queries on nutraceutical osteoarthritis reviews in dogs, Cosequin chewable tablets with MSM, and manganese ascorbate with osteoarthritis in dogs. Not exhaustive. Most records were abstracts only, so methods, amounts and funding are often unavailable. Excluded from dog evidence rows: the mesotherapy retrospective study (injected glucosamine in a drug combination), the turmeric extract trial (Glu/CS was only a comparator), the thyroid safety study (not an efficacy outcome), and the COAST guideline excerpt (no MSM or product data). Cat trials inside the 2022 meta-analysis were not counted as dog evidence.
Focused research searches:
- (TITLE_ABS:nutraceutical* AND TITLE_ABS:osteoarthrit* AND TITLE_ABS:systematic AND TITLE_ABS:review) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine)
- (TITLE_ABS:nutraceutical* AND TITLE_ABS:osteoarthrit* AND TITLE_ABS:systematic AND TITLE_ABS:review) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine) sort_cited:y
- (Cosequin AND Chewable AND Tablets AND with AND MSM) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine)
- (Cosequin AND Chewable AND Tablets AND with AND MSM) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine) sort_cited:y
- (TITLE_ABS:Manganese AND TITLE_ABS:ascorbate AND TITLE_ABS:osteoarthrit*) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine)
- (TITLE_ABS:Manganese AND TITLE_ABS:ascorbate AND TITLE_ABS:osteoarthrit*) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine) sort_cited:y
- No trial of Cosequin Chewable Tablets with MSM was found in this search.
- No dog research on MSM was retrieved.
- No studied daily amount in mg for glucosamine or chondroitin was reported in the retrieved sources.
- Survey methods behind the '#1 vet recommended' claim were not available.
- No independent test of this product's contents was found in the reviewed material.